Mrs Julian Muwanguzi-Karugaba

Laboratory Manager - Malaria CL3

United Kingdom

Email
Julian

Affiliations

Faculty of Infectious and Tropical Diseases

Centres

Malaria Centre

Selected Publications

Novel Pfk13 and Pfubp1 genotypes in African Plasmodium falciparum isolates exhibiting reduced susceptibility to the antimalarials artemisinin and lumefantrine.

PRATT, S; Van Schalkwyk, DA; Stewart, L; Hocke, EF; Mannan, S; Berry, C; MUWANGUZI-KARUGABA, J; Nolder, D; Rogers, C; Chiodini, PL; Henrici, RC; MOSS, S; BILLOWS, N; PHELAN, J; CLARK, TG; CAMPINO, S; SUTHERLAND, CJ;

2026

mBio

Treatment Failure in a UK Malaria Patient Harboring Genetically Variant Plasmodium falciparum From Uganda With Reduced In Vitro Susceptibility to Artemisinin and Lumefantrine.

VAN SCHALKWYK, DA; PRATT, S; NOLDER, D; STEWART, LB; Liddy, H; MUWANGUZI-KARUGABA, J; BESHIR, KB; Britten, D; Victory, E; Rogers, C; Millard, J; Brown, M; Nabarro, LE; Taylor, A; Young, BC; Chiodini, PL; SUTHERLAND, CJ;

2023

Clinical Infectious Diseases

Codon-optimized DsRed fluorescent protein for use in Mycobacterium tuberculosis.

Carroll, P; MUWANGUZI-KARUGABA, J; Parish, T;

2018

BMC research notes

Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan children.

Muwanguzi, J; HENRIQUES, G; Sawa, P; BOUSEMA, T; SUTHERLAND, CJ; BESHIR, KB;

2016

Malaria journal

K13 MUTATIONS IN PLASMODIUM FALCIPARUM PERSISTING AFTER ACT TREATMENT OF KENYAN CHILDREN

BESHIR, KB; MUWANGUZI-KARUGABA, J; Sawa, P; SUTHERLAND, C;